Quick Facts

• Condition Managed: Iron deficiency anemia.
• Patient Population: Individuals who may be intolerant to or have an unsatisfactory response to oral iron.
• Key Indication: Treatment of iron deficiency, including in patients with chronic kidney disease (CKD) where oral therapy may be less effective.

---

Encifer is an intravenous iron replacement product utilized in the clinical management of iron deficiency and associated iron deficiency anemia. The administration of this medicine is intended to help replenish the body’s iron stores, a necessary factor for the formation of red blood cells and oxygen transport.

The drug is typically utilized in patient populations where the administration of oral iron supplements is considered unsuitable, or where patients have demonstrated an unsatisfactory clinical response to oral iron therapy. A primary application is the treatment of iron deficiency, including in individuals with chronic kidney disease (CKD) who may require an alternative route of iron delivery.

Use of the medication is based on a healthcare professional’s assessment of appropriate laboratory tests, such as hemoglobin and serum ferritin levels, to confirm a diagnosis of iron deficiency. Encifer is indicated for use in these specific patient groups for its established therapeutic applications.

Regulatory References

1. Rwanda FDA therapeutic overview

Eligibility for Encifer (Iron Sucrose Complex)

Official regulatory documents strictly define the populations permitted and prohibited from using Encifer, an intravenous iron replacement medicine.

Contraindications (Who Must Not Use): Use is contraindicated in patients with a known hypersensitivity to the Iron Sucrose Complex or any of its components, and in individuals with existing iron overload (excessive iron stores). It is also prohibited for patients whose anemia is not caused by iron deficiency.

Approved Populations (Who Can Use): Encifer is primarily approved for treating Iron Deficiency Anemia (IDA) in adult and pediatric patients (2 years and older) who have Chronic Kidney Disease (CKD). This includes patients on hemodialysis, peritoneal dialysis, and those not on dialysis.

Conditional and Restricted Use:

• Pediatric Use: Safety and effectiveness have not been established in children under two years of age.
• Pregnancy: Use during pregnancy is advised only if clearly needed, as there are no adequate studies, and use is generally not recommended during the first trimester.
• Comorbidities: Caution is required for patients with liver dysfunction, acute or chronic infection, or a history of severe allergies/asthma.

Interactions with other medicines and products

Encifer (Iron Sucrose Complex) has a specific and narrowly defined interaction profile, as documented in official government regulatory information. The primary focus of the regulatory constraints is on co-administration with other iron products and maintaining procedural integrity during infusion.

Documented Interaction Patterns

Interacting Product Category	Official Interaction Outcome	Regulatory Restriction
Oral Iron Preparations	Parenteral iron may be expected to reduce the absorption of the oral iron product.	Oral iron therapy should be started at least 5 days after the final dose of Encifer injection.
Vasodilators (e.g., Iloprost)	Potential for pharmacodynamic synergism that may result in additive effects on blood pressure.	Requires professional assessment regarding temporary discontinuation or monitoring of the co-administered agent.

Procedural and Compatibility Constraints

Official prescribing information includes a strict procedural constraint: Encifer solution must not be mixed with other medicinal products or added to parenteral nutrition solutions for intravenous infusion. This restriction addresses the potential for precipitation or chemical incompatibility if the solution is combined with other substances outside of the established dilution protocol.

How Encifer Works: Mechanism of Action

Encifer acts as a source of polynuclear iron(III)-hydroxide which is selectively delivered to the body’s iron processing centers, primarily the reticuloendothelial system (RES). This initial action facilitates the augmentation of iron content within the storage pool (ferritin) via direct uptake by RES macrophages.

The iron is subsequently mobilized from the RES storage cells via the protein ferroportin and efficiently bound to the plasma transport protein, transferrin. This process of iron homeostasis modulation facilitates the transferrin-mediated distribution of iron into the systemic circulation, supporting iron availability for tissues with elevated metabolic requirements.

The transferrin-bound iron is then transported to the erythroid precursor cells in the bone marrow, the site of red blood cell component synthesis. Here, the iron is utilized to form heme, which is then incorporated into globin to synthesize functional hemoglobin. The resulting physiological consequence is the modulation of the oxygen transport potential within the circulatory system.

How Encifer is Used: Administration Overview

Encifer is an Intravenous (IV) Solution; administration is performed under clinical supervision, either by slow IV injection, drip infusion, or directly into the venous line during a hemodialysis session. Doses are standardized and measured in milligrams (mg) of elemental iron.

---

Dosing and Frequency Patterns

The total treatment course for iron replacement is typically 1000 mg of elemental iron. The schedule for administration depends upon the specific type of chronic kidney disease (CKD) being managed. For patients with hemodialysis-dependent CKD, the dose is commonly 100 mg administered per consecutive dialysis session until the total target dose is reached. For non-dialysis dependent CKD patients, the total dose may be divided into 200 mg administrations, given on five separate occasions over a 14-day period.

---

Preparation and Infusion Constraints

Preparation involves diluting the solution immediately before use, utilizing only sterile 0.9% sodium chloride solution. The concentration of the diluted solution is maintained at no lower than 1 mg of elemental iron per mL. Minimum infusion times are utilized to ensure controlled delivery; for example, a 100 mg dose is infused over at least 15 minutes. The medicine is not mixed with other therapeutic agents in the administration line.

---

Population-Specific Use

Dosing for iron maintenance in pediatric patients (two years and older) is established at 0.5 mg/kg (not to exceed 100 mg per dose), administered on an intermittent schedule depending on the patient's CKD status. Dosing for iron replacement treatment in pediatric patients has not been established.

Research evidence / Overview of Studies for Encifer

This overview describes the types of scientific studies that have been conducted to evaluate Encifer (Iron Sucrose Complex) and the research landscape supporting its use. This information is drawn only from authoritative scientific and regulatory sources.

---

Evidence for Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD)

Research has explored Iron Sucrose Complex in patients with IDA linked to Chronic Kidney Disease (CKD) across various research settings, including Randomized Controlled Trials (RCTs) and comparative studies. Researchers have specifically looked at populations with CKD across different stages, including those on hemodialysis, peritoneal dialysis, and those not yet requiring dialysis.

The primary focus of these studies was to monitor Hematological Parameters and iron status biomarkers. Research monitored key markers like Hemoglobin (Hb) and measures of iron stores, such as Serum Ferritin and Transferrin Saturation (TSAT), over defined observation periods. Findings describe patterns observed in these biomarkers over short-term to intermediate periods (e.g., up to 12 weeks) when studied against other iron replacement methods. Long-term clinical outcomes beyond these biomarker corrections remain uncertain.

---

Evidence for Iron Deficiency Anemia (IDA) in Pregnancy

For the study of IDA during pregnancy, especially when oral iron is unsuitable or not effective, research has explored outcomes related to the medicine through Randomized Controlled Trials (RCTs) and systematic reviews. The primary research goal was to examine specific outcomes in the mother, including physical markers and systemic balance markers (referring to the Hb and anaemia prevalence).

Studies monitored changes in Antenatal and Postpartum Hemoglobin (Hb) levels and examined patterns related to the prevalence of anaemia. Researchers also looked at whether the medicine was observed in studies to relate to changes in the need for Blood Transfusion around the time of delivery.

---

Research Gaps and Areas of Uncertainty

One key limitation is that the primary endpoints in many studies are blood biomarkers (Hemoglobin, Ferritin) and not long-term functional measures or major clinical outcomes like hospitalization or quality of life. Therefore, long-term effects are not fully established.

Additionally, while evidence quality varies across studies, some of the foundational data utilized open-label or historical controls. The data for certain groups remain insufficient, meaning that personalized outcomes are not determined by the group findings, and the comparative evidence is lacking for some of the potential ways the medicine could be studied.

Key Studies & References

1. Evaluation of therapeutic response and tolerability to intravenous iron sucrose and ferric carboxymaltose among pregnant women with iron‑deficiency anemia (Observational Study)

Common questions about Encifer (FAQ)

---

Q: What types of heart conditions make someone ineligible for Encifer?

Official regulatory information notes that caution is needed for patients who have decreased cardiac function (heart function). Furthermore, the medicine may cause clinically significant hypotension (low blood pressure). These considerations are reflected in the risk profile for the medicine.

---

Q: Can people with liver problems use Encifer?

According to the official product information, patients with liver disease or severe hepatic impairment require caution when the medicine is used. The dose selection, especially in older patients, often reflects the possibility of decreased liver function. Any use in this population is determined by clinical review.

---

Q: Can Encifer be taken during pregnancy?

Official regulatory labels advise against the use of this medicine during the first trimester of pregnancy. Use during the second and third trimesters is reserved for situations where the potential benefit is determined to clearly outweigh the risks. This is due to reports that severe reactions in the mother may cause fetal bradycardia (a slow fetal heart rate).

---

Q: Have there been long-term studies published about Encifer?

Studies, including long-term clinical trials, have been published concerning this medicine. However, while official information indicates these studies track hematological markers (blood components), the long-term effects on major clinical outcomes beyond those initial biomarker corrections are not fully established.

---

Q: Are there specific symptoms that require immediate medical attention while taking Encifer?

Yes. Official warnings highlight that symptoms of serious hypersensitivity reactions (severe allergic reactions) and hypotension are signals of a serious event. These symptoms can include trouble breathing, sudden rash, itching, swelling of the face or throat, shock, collapse, or loss of consciousness.

---

Q: Why does Encifer have to be taken regularly?

The medicine is administered as part of a total, cumulative treatment course to safely replenish the body's deficient iron stores. This treatment is divided over multiple scheduled sessions to ensure controlled delivery of iron.

---

Q: Is there a maximum amount of time someone can be on Encifer?

Official labeling specifies a defined total amount of medicine for the initial treatment course. The treatment may be repeated if subsequent blood tests indicate that iron deficiency has returned. There is no specific stated lifetime maximum duration mentioned in the regulatory documents.

---

Q: Are the side effects of Encifer usually severe?

The majority of adverse reactions reported in clinical trials are classified as Common, such as headache, nausea, and low blood pressure. More serious adverse reactions like convulsions or fainting (syncope) are classified as Rare.

---

Q: Is it safe to drink alcohol while taking Encifer?

Official patient safety summaries describe the need to inform the care provider about alcohol use. Consuming alcohol may increase the risk of side effects like dizziness, which is a possible adverse reaction to the medicine.

---

Q: Are there restrictions on driving or operating machinery while taking Encifer?

Official patient safety information indicates that caution is necessary regarding these activities. The medicine may cause side effects such as dizziness which could impair driving or operating machinery.

---

Q: Is Encifer known to be habit-forming?

No. Official regulatory classification indicates that Encifer (Iron Sucrose Complex) is not classified as a controlled substance. The medicine is not known to be habit-forming.

---

Q: What is the source of the research evidence for Encifer?

The research evidence is the specific clinical trial data that was submitted to and reviewed by government regulatory bodies, such as the FDA and the EMA. The findings from these trials are summarized and detailed in the official product labeling.

---

Q: Why do some people need to have blood tests while taking Encifer?

Monitoring iron levels and response (such as changes in Hemoglobin) is conducted to help manage the risk of iron overload. It also helps confirm that the medicine is achieving the desired hematologic response.

---

Q: Does Encifer cause changes in mood or personality?

Official post-marketing experience data has reported rare instances of confusion among patients, which is listed under Psychiatric Disorders in the safety profile.

---

Q: Is Encifer available in different strengths?

Yes, the solution for intravenous use is available in multiple single-dose vial strengths. The different strength options allow for flexibility in administration during clinical supervision.

---

Q: Why is it important to tell the doctor about all other medicines?

It is important because official regulatory warnings indicate that the medicine may reduce the absorption of certain oral iron preparations that are administered concurrently. The disclosure of all medicines is important due to this regulatory warning.

---

Q: If someone is allergic to Encifer, what are the typical reactions?

Reported reactions can range from mild effects like itching, skin rash, or hives to nausea, vomiting, stomach cramps, and joint pain. Patients are monitored closely by healthcare providers for these and any more severe reactions following administration.

---

Q: Does the time of day matter when taking Encifer?

Regulatory information specifies that for certain patient groups, the medicine is administered during a specific time period of a scheduled treatment session. This is part of the established administration protocol.

---

Q: Can men and women use Encifer in the same way?

Yes, the official dosing instructions are based on the patient’s Chronic Kidney Disease status and body weight (for pediatric patients). Regulatory information does not require adjustments based on gender.

---

Q: Is there a patient information leaflet available for Encifer online?

Yes, official patient safety guides, Medication Guides, and comprehensive patient information leaflets are publicly available and distributed by regulatory agencies, such as the FDA and the EMA.

---

Q: Why is Encifer sometimes prescribed in combination with other drugs?

Clinical studies have examined the medicine's use in combination with Erythropoiesis-Stimulating Agents (ESAs). This combination is studied as a means to help manage iron deficiency while promoting red blood cell production.

Storage and Disposal of Encifer (Iron Sucrose Injection)

Encifer must be stored and handled according to specific conditions defined by regulatory labeling to maintain its stability and single-dose sterility.

Mandatory Storage Requirements

• Temperature: Store below 30 °C. The product must not be frozen.
• Light Protection: The medication must be kept in the original package to protect the solution from light.

Handling and Stability

Encifer is a preservative-free, single-dose solution, necessitating strict handling protocols. The solution must be visually inspected for particulate matter or discoloration prior to administration. If dilution is required, it must take place immediately prior to infusion, using only sterile 0.9% m/V sodium chloride solution.

Disposal Instructions

As the product is for single-dose use, any unused solution, including any unused diluted solution, must be discarded. Disposal of the unused product and waste material must be done in accordance with all applicable local requirements for pharmaceutical waste.